Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis

Leuk Lymphoma. 2022 Aug;63(8):1980-1984. doi: 10.1080/10428194.2022.2057487. Epub 2022 Apr 28.
No abstract available

Keywords: COVID-19; CAR-T; SARS-CoV-2.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*
  • SARS-CoV-2
  • United Kingdom / epidemiology

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen